If the FDA goes through with plans to recommend that hydrocodone combination drugs be reclassified as Schedule II, it should limit the reclassification to those drugs that contain 5 mg or more of hydrocodone bitartrate. Read More
Dendreon Corp., of Seattle, made four abstract presentations on Provenge (sipuleucel-T) and one abstract for DN24-02, an investigational active cellular immunotherapy, from ongoing clinical trials at the 2014 Genitourinary Cancers Symposium (ASCO GU). Read More
Cardiome Pharma Corp., of Vancouver, British Columbia, said it filed a preliminary short form base shelf prospectus with securities regulatory authorities in Canada, other than Quebec, and a corresponding shelf registration statement with the U.S. SEC. Read More
Alexion Pharmaceuticals Inc. pleasantly surprised both investors and analysts alike with fourth quarter financials that were well ahead of expectations. Read More
LONDON – Researchers have for the first time identified some of the bacteria that live within marine sponges, and which have novel ways of synthesising metabolites that could one day provide new antibiotics or drugs to treat cancer. Read More
While a growing number of the drugs imported into the U.S. are from Asian countries, Ireland remains by far the No. 1 supplier of U.S. drugs. Read More
LONDON – Nightstarx Ltd. has been launched with £12 million (US$19.8 million) funding to commercialize a gene therapy that has been demonstrated to partly restore vision in patients losing their eyesight as a result of the X-linked inherited disorder, choroideremia. Read More
In what has now become almost blandly – though happily – routine in the biopharma sector, two more companies went public via initial public offerings (IPOs) Thursday amid a heap of other financings news. Read More
Johnson & Johnson, of New Brunswick, N.J., reported that its subsidiary, Janssen Research and Development LLC, has entered into an agreement with Yale School of Medicine’s Open Data Access (YODA) Project that will extend its commitment to sharing clinical trials data to enhance public health and advance science and medicine. Read More
